Assembly Biosciences advances viral drug candidates and plans Phase 2 for hepatitis delta in late 2026

Assembly Biosciences reported steady progress in Q1 2026, completing Phase 1b studies for two herpes drug candidates and chronic toxicology studies for a hepatitis delta virus (HDV) drug. The company expects to start a Phase 2 trial for ABI-6250 in Q4 2026 and will decide mid-year whether to opt into a cost-profit share with Gilead for their herpesvirus program. Financially, Assembly Biosciences ended Q1 with $226.6 million in cash, projecting funding into 2028, and reported a net loss of $9.1 million. These developments highlight ongoing advancements in treatments for serious viral diseases with upcoming clinical milestones and collaborations.